Research Peptide Price Guide · Updated April 2026

Retatrutide Price Guide 2026: How Much Does It Cost?

Retatrutide is the most-watched peptide compound of 2026 — a triple-receptor agonist that activates GLP-1, GIP, and glucagon pathways simultaneously, and the only compound to show average weight loss exceeding 24% of body weight in Phase 2 clinical trials. It is not yet FDA-approved and is sold for research purposes only. This guide covers what research-grade retatrutide costs today, which suppliers carry it, and what to expect as the market evolves ahead of potential approval.

⚡ Active Phase 3 trials — pricing will change Retatrutide is in Eli Lilly's TRIUMPH Phase 3 program. Research-grade supply is limited and prices are higher than established peptides. As the compound progresses toward potential approval and more suppliers enter the market, per-milligram costs are expected to decline — the same trajectory seen with tirzepatide from 2022 to 2026.
$83.99
5mg Starting Price
Spectrum Peptides, April 2026
$15.99/mg
Best Price Per mg
Spectrum Peptides 10mg
~24%
Avg. Weight Loss
Phase 2 trial, 48 weeks

Current Retatrutide Research Peptide Prices

Prices below are sourced from supplier websites and updated nightly by our automated tracker. Fewer suppliers currently carry retatrutide compared to established peptides like semaglutide or BPC-157. All prices are in USD.

Small Vials (5–10mg)

SupplierSizePricePrice / mgLocation
Spectrum Peptides Best Value 5mg$83.99$16.80/mgUSA
Spectrum Peptides Best /mg Small 10mg$165.99$15.99/mg ↓ bestUSA
Peptide Lab 10mg$150.00$15.00/mgUSA

Bulk Vials (15–60mg) — Peptide Lab

SizePricePrice / mgvs. 10mg rate
15mg$200.00$13.33/mg11% cheaper/mg
20mg$250.00$12.50/mg17% cheaper/mg
30mg$300.00$10.00/mg33% cheaper/mg
40mg$300.00$7.50/mg50% cheaper/mg ★
50mg$350.00$7.00/mg53% cheaper/mg
60mg$400.00$6.67/mg56% cheaper/mg
💡 Bulk pricing drops sharply at 40mg+ Peptide Lab's pricing curve has a notable inflection at 40mg — the price holds flat from 30mg to 40mg ($300 each), meaning the 40mg vial delivers 50% more peptide for the same price. The 40mg at $7.50/mg is the standout bulk value. Verify current availability directly with the supplier before planning a large order.

What Is Retatrutide?

Retatrutide (Eli Lilly compound designation: LY3437943) is a synthetic peptide that simultaneously agonizes three distinct receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GcgR). This triple-agonist mechanism sets it apart from every GLP-1 drug currently on the market.

Tirzepatide (Mounjaro, Zepbound), currently the most effective approved weight-loss drug, activates two receptors: GLP-1 and GIP. Retatrutide adds glucagon receptor activation, which increases energy expenditure — essentially accelerating the body's calorie-burning rate on top of the appetite suppression and insulin-sensitizing effects of the first two pathways.

Retatrutide Clinical Trial Results

Retatrutide's Phase 2 data published in the New England Journal of Medicine (2023) made it one of the most-discussed compounds in metabolic medicine:

2023 — Phase 2 Results Published
At 48 weeks, participants receiving the highest dose (12mg weekly) achieved an average weight reduction of 24.2% of body weight. This exceeded results from Phase 3 semaglutide (15–17%) and tirzepatide (20–22%) trials, though direct comparison across trials is methodologically limited.
2023–2024 — Phase 3 TRIUMPH Program Initiated
Eli Lilly launched the TRIUMPH Phase 3 clinical program, a series of large-scale trials examining retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes.
2025–2026 — Phase 3 Ongoing
TRIUMPH trials continue enrollment and follow-up. No FDA submission has been made as of April 2026. Lilly has indicated retatrutide is on track but has not given specific approval timeline guidance.
Estimated 2027–2028 — Potential Approval Window
Based on typical Phase 3 timelines and FDA review periods, potential approval could come in 2027–2028 if trials succeed and Lilly submits a New Drug Application. This is an estimate, not a commitment.
⚠️ Clinical trial data ≠ approved drug Retatrutide's Phase 2 results are promising but represent a single trial in a controlled setting. Phase 3 data may differ, and FDA approval is not guaranteed. Research-grade retatrutide is not the same product used in clinical trials and carries no clinical oversight or quality assurance equivalent to a pharmaceutical product.

Retatrutide vs. Semaglutide vs. Tirzepatide

PropertySemaglutideTirzepatideRetatrutide
Receptor targetsGLP-1GLP-1 + GIPGLP-1 + GIP + Glucagon
DeveloperNovo NordiskEli LillyEli Lilly
FDA approval statusApproved (Ozempic, Wegovy)Approved (Mounjaro, Zepbound)Phase 3 — Not approved
Phase 2 avg. weight loss~15–17%~20–22%~24% (highest dose)
Dosing frequencyOnce weeklyOnce weeklyOnce weekly (trials)
Brand-name Rx price/mo$800–$1,100$900–$1,200Not available (unapproved)
Research peptide (10mg)~$130–$200~$100–$180~$150–$166

Is Retatrutide Legal to Buy?

In the United States, retatrutide is not FDA-approved and is not a scheduled controlled substance. Research peptide suppliers sell it legally as a research chemical for laboratory use only, with explicit "not for human consumption" labeling. It is not legal to sell it as a drug or for therapeutic purposes without FDA approval.

Because retatrutide is actively in clinical development by Eli Lilly, the research chemical market operates somewhat differently from compounds with no pharmaceutical development pathway. Eli Lilly holds patents on retatrutide; research chemical suppliers synthesize their own versions independently, which is common practice in the research peptide industry.

WADA has not specifically listed retatrutide on its prohibited list as of 2026, though its GLP-1 agonist activity means it could fall under existing prohibited substance categories. Competitive athletes should seek specific guidance from their sport's anti-doping authority.

Notable Research Suppliers (2026)

Spectrum Peptides

$83.99· $16.80/mg (5mg)
USA-based. Currently the only tracked supplier offering a 5mg entry vial. Best per-mg rate on standard sizes at $15.99/mg for 10mg. Competitive across the catalog with transparent pricing.

Peptide Lab

$150.00· $15.00/mg (10mg)
USA-based. Slightly better per-mg on 10mg than Spectrum. Unique advantage: the only supplier currently offering bulk sizes up to 60mg, with rates as low as $6.67/mg at the 60mg tier. Large-order researchers should compare carefully.
⚠️ Limited supplier availability Only two suppliers in our current tracking database carry retatrutide. As a newer, more complex peptide in active Phase 3 development, supply chains are less mature than for established compounds. Check our live price comparison tool for the most current availability.

What to Look for in a Retatrutide Supplier

Retatrutide is a longer, more structurally complex peptide than most in the research market. Quality verification is especially important:

Frequently Asked Questions

How much does retatrutide cost in 2026?

Research-grade retatrutide currently ranges from $83.99 for a 5mg vial (Spectrum Peptides) to $165.99 for a 10mg vial (also Spectrum). Peptide Lab offers larger bulk sizes up to 60mg at prices as low as $6.67/mg. The market has limited supplier competition, which keeps prices higher than more established peptides. Use our live price comparison tool for current figures.

Will retatrutide become cheaper over time?

Almost certainly yes, as more suppliers enter the market and synthesis processes mature. Tirzepatide research peptide prices fell significantly between 2022 and 2026 as it became more widely available. Retatrutide is likely to follow the same curve, with the fastest price drops occurring once Eli Lilly receives FDA approval (if successful) and public awareness spikes demand that brings more suppliers in.

Is retatrutide available as a prescription medication?

No. As of April 2026, retatrutide is not FDA-approved and is not available as a prescription drug in the United States. Eli Lilly is conducting Phase 3 TRIUMPH trials, and no NDA submission has been made. There is no legal route to obtain pharmaceutical retatrutide outside of a clinical trial.

How does retatrutide's glucagon receptor action help with weight loss?

The glucagon receptor, when activated, increases the liver's glucose output and raises the body's basal metabolic rate — it effectively increases energy expenditure. In isolation, glucagon activation can cause hyperglycemia, which is why glucagon agonists haven't been developed standalone. When combined with GLP-1 agonism (which lowers blood glucose and suppresses appetite) and GIP agonism (which enhances insulin sensitivity), the three pathways balance each other. The net result is increased calorie burning without the blood sugar spike that pure glucagon activation would cause.

What supplies are needed for retatrutide research?

Standard peptide research supplies: bacteriostatic water for reconstitution, insulin syringes (29–31 gauge, 1cc), alcohol prep pads, and a sharps container. These are available on Amazon. See our peptide supplies section for curated options.

Medical & Legal Disclaimer: Retatrutide is an investigational compound currently in Phase 3 clinical trials. Research-grade retatrutide sold by peptide suppliers is not intended for human consumption and is not an FDA-approved drug. Nothing on this page constitutes medical advice, investment advice regarding Eli Lilly, or an endorsement of any supplier. Clinical trial results (Phase 2) are preliminary and not a guarantee of Phase 3 outcomes or eventual FDA approval. All price data is sourced from publicly available supplier websites and is subject to change — always verify pricing directly with the supplier. BetterNewLives.com earns affiliate commissions from some links on this site; this does not affect our price reporting or rankings.